@Article{ujfe735,
AUTHOR = {Tawfik, Hadeer Abdel-Aleem Hassan Mohamed and Farres, Mohamed Nazmy and Samir, Rasha and Ashram, Mohamed Nabil Badawy Al and Nessim, Mina Mikhail and Allam, Mohamed Farouk},
TITLE = {Effectiveness of Probiotics for Treatment of COVID-19: A Systematic Review and Meta-analysis},
JOURNAL = {Universal Journal of Finance and Economics},
VOLUME = {1},
YEAR = {2023},
NUMBER = {1},
PAGES = {17-25},
URL = {https://www.scipublications.com/journal/index.php/UJGH/article/view/735},
ISSN = {2832-4587},
DOI = {10.31586/ujgh.2023.735},
ABSTRACT = {Background: Recently specific interactions and crosslinks between the gut microbiota and the lungs have been recognized, particularly with regard to respiratory immune and anti-microbial reactions. This is often known as the “gut-lung axis” or “a common mucosal immunological system”. Objective: The aim of the current systematic review was to evaluate evidence, from published clinical trials and cohort studies, if probiotics may have an effect in improving and managing COVID-19 symptoms. Materials and methods: The available studies were searched through a comprehensive search of electronic databases that included PubMed, Science Direct, Scirus, ISI Web of Knowledge, Google Scholar and CENTRAL (Cochrane Central Register of Controlled Trials), using a combination of the following keywords: “COVID-19" OR "SARS-CoV-2" AND "Microbiota" OR "Probiotics” OR “Gut Lung Axis”. The literature was reviewed until August 31, 2022. Results: Only 3 studies were included. One of them evaluated the efficacy of probiotics in COVID-19 patients to obtain complete remission of all signs and symptoms. The clinical trial proves that probiotics have a significant effect on complete remission of all signs and symptoms of COVID-19 patients with statistical significant difference. Only one clinical trial out of the 3 included studies had evaluated the need for O2 therapy during the study between the probiotics and control groups, but without statistical significant difference. No statistical significant difference between the probiotics group and placebo group was observed regarding fatal prognosis during the only clinical trial that measured death as an outcome. Conclusion: We couldn’t judge on these results as they are insufficient data for pooling and meta-analysis. However, what we can say is “Most probably Probiotics have no role in treatment of COVID-19 infection”.},
}

%0 Journal Article
%A Tawfik, Hadeer Abdel-Aleem Hassan Mohamed
%A Farres, Mohamed Nazmy
%A Samir, Rasha
%A Ashram, Mohamed Nabil Badawy Al
%A Nessim, Mina Mikhail
%A Allam, Mohamed Farouk
%D 2023
%J Universal Journal of Finance and Economics

%@ 2832-4587
%V 1
%N 1
%P 17-25

%T Effectiveness of Probiotics for Treatment of COVID-19: A Systematic Review and Meta-analysis
%M doi:10.31586/ujgh.2023.735
%U https://www.scipublications.com/journal/index.php/UJGH/article/view/735

TY  - JOUR
AU  - Tawfik, Hadeer Abdel-Aleem Hassan Mohamed
AU  - Farres, Mohamed Nazmy
AU  - Samir, Rasha
AU  - Ashram, Mohamed Nabil Badawy Al
AU  - Nessim, Mina Mikhail
AU  - Allam, Mohamed Farouk
TI  - Effectiveness of Probiotics for Treatment of COVID-19: A Systematic Review and Meta-analysis
T2  - Universal Journal of Finance and Economics
PY  - 2023
VL  - 1
IS  - 1
SN  - 2832-4587
SP  - 17
EP  - 25
UR  - https://www.scipublications.com/journal/index.php/UJGH/article/view/735
AB  - Background: Recently specific interactions and crosslinks between the gut microbiota and the lungs have been recognized, particularly with regard to respiratory immune and anti-microbial reactions. This is often known as the “gut-lung axis” or “a common mucosal immunological system”. Objective: The aim of the current systematic review was to evaluate evidence, from published clinical trials and cohort studies, if probiotics may have an effect in improving and managing COVID-19 symptoms. Materials and methods: The available studies were searched through a comprehensive search of electronic databases that included PubMed, Science Direct, Scirus, ISI Web of Knowledge, Google Scholar and CENTRAL (Cochrane Central Register of Controlled Trials), using a combination of the following keywords: “COVID-19" OR "SARS-CoV-2" AND "Microbiota" OR "Probiotics” OR “Gut Lung Axis”. The literature was reviewed until August 31, 2022. Results: Only 3 studies were included. One of them evaluated the efficacy of probiotics in COVID-19 patients to obtain complete remission of all signs and symptoms. The clinical trial proves that probiotics have a significant effect on complete remission of all signs and symptoms of COVID-19 patients with statistical significant difference. Only one clinical trial out of the 3 included studies had evaluated the need for O2 therapy during the study between the probiotics and control groups, but without statistical significant difference. No statistical significant difference between the probiotics group and placebo group was observed regarding fatal prognosis during the only clinical trial that measured death as an outcome. Conclusion: We couldn’t judge on these results as they are insufficient data for pooling and meta-analysis. However, what we can say is “Most probably Probiotics have no role in treatment of COVID-19 infection”.
DO  - Effectiveness of Probiotics for Treatment of COVID-19: A Systematic Review and Meta-analysis
TI  - 10.31586/ujgh.2023.735
ER  -